Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 157 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total transaction of $10,048.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Foundation Medicine Inc (NASDAQ FMI) traded up $0.45 on Wednesday, hitting $63.05. The company had a trading volume of 184,187 shares, compared to its average volume of 338,680. Foundation Medicine Inc has a 12 month low of $17.10 and a 12 month high of $70.75. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47. The company has a market cap of $2,290.00, a PE ratio of -14.11 and a beta of -0.01.

Foundation Medicine (NASDAQ:FMI) last issued its earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The company had revenue of $42.66 million for the quarter, compared to analysts’ expectations of $37.99 million. During the same period last year, the business earned ($0.90) EPS. Foundation Medicine’s quarterly revenue was up 45.0% compared to the same quarter last year. analysts anticipate that Foundation Medicine Inc will post -4.44 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Chevy Chase Trust Holdings Inc. lifted its holdings in shares of Foundation Medicine by 1.1% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,059,141 shares of the company’s stock worth $42,572,000 after purchasing an additional 11,934 shares in the last quarter. Discovery Group I LLC lifted its holdings in shares of Foundation Medicine by 0.9% in the 3rd quarter. Discovery Group I LLC now owns 836,986 shares of the company’s stock worth $33,647,000 after purchasing an additional 7,181 shares in the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Foundation Medicine by 5.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 723,480 shares of the company’s stock worth $29,084,000 after purchasing an additional 39,390 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Foundation Medicine by 8.2% in the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after purchasing an additional 47,843 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its holdings in shares of Foundation Medicine by 146.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock worth $23,024,000 after purchasing an additional 343,770 shares in the last quarter. Institutional investors own 32.68% of the company’s stock.

Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Foundation Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Foundation Medicine has an average rating of “Hold” and a consensus target price of $45.33.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/03/insider-selling-foundation-medicine-inc-fmi-coo-sells-157-shares-of-stock.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.